Scott Biller Sells 2,146 Shares of Agios Pharmaceuticals, Inc. (AGIO) Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Scott Biller sold 2,146 shares of the stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $62.69, for a total value of $134,532.74. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Scott Biller also recently made the following trade(s):

  • On Wednesday, October 4th, Scott Biller sold 10,470 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $70.00, for a total value of $732,900.00.
  • On Monday, October 2nd, Scott Biller sold 2,146 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $67.23, for a total value of $144,275.58.
  • On Monday, September 11th, Scott Biller sold 15,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $65.00, for a total value of $975,000.00.
  • On Friday, September 1st, Scott Biller sold 2,146 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $61.99, for a total value of $133,030.54.

Shares of Agios Pharmaceuticals, Inc. (AGIO) opened at $66.49 on Friday. Agios Pharmaceuticals, Inc. has a 12 month low of $39.24 and a 12 month high of $72.73.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.78) by $0.19. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. The business had revenue of $11.35 million during the quarter, compared to analyst estimates of $10.85 million. During the same quarter in the prior year, the business posted ($1.63) EPS. Agios Pharmaceuticals’s revenue for the quarter was up 26.4% compared to the same quarter last year. equities analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.69 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Scott Biller Sells 2,146 Shares of Agios Pharmaceuticals, Inc. (AGIO) Stock” was reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.com-unik.info/2017/11/05/scott-biller-sells-2146-shares-of-agios-pharmaceuticals-inc-agio-stock.html.

Hedge funds have recently modified their holdings of the business. Spark Investment Management LLC increased its stake in Agios Pharmaceuticals by 139.9% in the 2nd quarter. Spark Investment Management LLC now owns 84,700 shares of the biopharmaceutical company’s stock worth $4,357,000 after buying an additional 49,400 shares in the last quarter. Geode Capital Management LLC increased its stake in Agios Pharmaceuticals by 8.3% in the 1st quarter. Geode Capital Management LLC now owns 263,899 shares of the biopharmaceutical company’s stock worth $15,410,000 after buying an additional 20,336 shares in the last quarter. Hood River Capital Management LLC increased its stake in Agios Pharmaceuticals by 2.3% in the 2nd quarter. Hood River Capital Management LLC now owns 118,844 shares of the biopharmaceutical company’s stock worth $6,115,000 after buying an additional 2,626 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Agios Pharmaceuticals by 4.9% in the 2nd quarter. Goldman Sachs Group Inc. now owns 681,093 shares of the biopharmaceutical company’s stock worth $35,042,000 after buying an additional 31,969 shares in the last quarter. Finally, TD Asset Management Inc. increased its stake in Agios Pharmaceuticals by 4.9% in the 2nd quarter. TD Asset Management Inc. now owns 30,000 shares of the biopharmaceutical company’s stock worth $1,544,000 after buying an additional 1,400 shares in the last quarter. Institutional investors and hedge funds own 93.46% of the company’s stock.

AGIO has been the subject of several analyst reports. ValuEngine upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Royal Bank Of Canada initiated coverage on Agios Pharmaceuticals in a research note on Thursday, September 14th. They issued an “outperform” rating and a $78.00 price objective for the company. J P Morgan Chase & Co restated a “buy” rating and issued a $76.00 price objective on shares of Agios Pharmaceuticals in a research note on Monday, September 18th. BidaskClub upgraded Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 13th. Finally, SunTrust Banks, Inc. restated a “buy” rating and issued a $80.00 price objective on shares of Agios Pharmaceuticals in a research note on Wednesday, October 4th. Three research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Agios Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $75.70.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

What are top analysts saying about Agios Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Agios Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit